Atherosclerosis plus最新文献

{"title":"Apolipoprotein B/LDL-C discordance and lipoprotein(a) as predictors of ASCVD risk in genetically confirmed heterozygous familial hypercholesterolemia (HeFH): A Retrospective Cohort Study (2005–2023)","authors":"N. Genedy, S.A. Zouwail","doi":"10.1016/j.athplu.2025.10.006","DOIUrl":"10.1016/j.athplu.2025.10.006","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 3-4"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Familial Chylomicronaemia Syndrome with Lomitapide","authors":"N. Lorde, A. Ochoa-Ferraro, S. Wanninayake, L. Robertson, C. Dawson","doi":"10.1016/j.athplu.2025.10.019","DOIUrl":"10.1016/j.athplu.2025.10.019","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 10"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond LDL: Uncovering residual cardiovascular risk in familial hypercholesterolemia – the MATCH-FH cohort study","authors":"N. Genedy, S.A. Zouwail","doi":"10.1016/j.athplu.2025.10.018","DOIUrl":"10.1016/j.athplu.2025.10.018","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 10"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Midlife ICAM-1 levels may predict cardiovascular disease and cognitive decline in latelife: Insights from the HeartSCORE study","authors":"Khaled Abdoun ,&nbsp;Justin Swanson ,&nbsp;Ian Pollack ,&nbsp;Yuefang Chang ,&nbsp;Kevin Kip ,&nbsp;Oscar L. Lopez ,&nbsp;Ann Cohen ,&nbsp;Steven Reis ,&nbsp;Anum Saeed","doi":"10.1016/j.athplu.2025.10.001","DOIUrl":"10.1016/j.athplu.2025.10.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic inflammation is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD) and has also been implicated in the progression of neuroinflammation. However, the relationship between inflammation and the combined risk of ASCVD and cognitive decline—particularly during the critical transition from midlife to late life—remains poorly understood. Identifying a shared inflammatory marker that signals vulnerability to both conditions may be an important tool for early intervention. In this study, we examined how baseline inflammatory markers, as well as their changes over one year, relate to long-term risk of ASCVD and cognitive outcomes.</div></div><div><h3>Methods</h3><div>We analyzed baseline and one-year change (1y-Δ) in an inflammatory biomarker panel [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), intracellular Adhesion Molecule 1 (ICAM-1) and CD40 ligand (CD40L_)] in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study. Using logistic and linear Cox regression models, the association of inflammatory markers and 1y-Δ, cognitive assessment by MoCA score, coronary artery calcium (CAC), carotid intima-media thickness (CIMT), and major adverse cardiovascular events (MACE) events were assessed longitudinally. All data were adjusted for the pooled cohort equation (PCE) risk factors and area under the receiver operating characteristic curve (AUC) were calculated for incremental risk prediction.</div></div><div><h3>Results</h3><div>Among 673 participants (mean age 59 ± 6.8 years; 63.9 % female; 31.6 % Black) were followed for 12 years. While both hs-CRP and IL-6 were associated with MACE events at 12 years, only ICAM-1 was linked with long-term MACE (HR 2.34 [1.02–5.37], p &lt; 0.05) as well as lower MoCA scores (β: 0.47 [95 % CI: 0.93 to −0.02], p &lt; 0.05). Compared to the PCE model, inflammatory biomarkers improved risk prediction indices for MACE (0.812, ΔAUC +0.056, p = 0.02) and MoCA (0.664, ΔAUC +0.04, p = 0.048). One-year biomarker changes were not significant for endpoint association.</div></div><div><h3>Conclusions</h3><div>In a community cohort of adults, midlife levels of three inflammatory markers (hs-CRP, IL-6, and ICAM-1) were predictive of late life ASCVD; however, only ICAM-1 was identified as a dual marker for ASCVD and cognitive impairment. The role of ICAM-1 as a prognostic marker for adverse cardiovascular and cognitive health should be explored in future studies.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 15-20"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145364116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of selected LDLR substitutions in patients with familial hypercholesterolemia","authors":"Monika Targońska ,&nbsp;Anna Janaszak-Jasiecka ,&nbsp;Magdalena Chmara ,&nbsp;Monika Żuk ,&nbsp;Leszek Kalinowski ,&nbsp;Krzysztof Waleron ,&nbsp;Jacek Jasiecki ,&nbsp;Bartosz Wasąg","doi":"10.1016/j.athplu.2025.11.001","DOIUrl":"10.1016/j.athplu.2025.11.001","url":null,"abstract":"<div><h3>Background and aims</h3><div>Familial hypercholesterolemia is a genetic disorder caused by pathogenic or likely pathogenic variants in four key genes: <em>LDLR</em>, <em>APOB</em>, <em>PCSK9,</em> and <em>APOE</em>. It leads to elevated levels of low-density lipoprotein cholesterol in the bloodstream and significantly increases the risk of coronary artery disease. This study aimed to functionally characterize <em>LDLR</em> variants identified in Polish FH patients. Experimental data were used to learn about variants' phenotypes and incorporate them into the ACMG/AMP variant classification framework.</div></div><div><h3>Methods</h3><div>The functional analysis was performed using the HEK293T-<em>ldlr</em>G1 cells with the expression vectors pTetRedLDLR carrying the mutated <em>LDLR</em> gene variants. Receptor expression was evaluated using Western blot and immunofluorescence. The low-density lipoprotein uptake and ligand binding capacity were examined with fluorescent dye-labeled LDL by confocal microscopy. A functional study was performed to analyze the variants under assessment and compare them to known benign and pathogenic control variants.</div></div><div><h3>Results</h3><div>The experimental study revealed an impaired activity of the c.662A &gt; G p. (Asp221Gly), c.1775G &gt; A p. (Gly592Glu), and c.2483delA p. (Tyr828Phefs∗101) <em>LDLR</em> variants, classifying them as functionally abnormal. In contrast, <em>in vitro</em> activity assessment of the c.91G &gt; A p. (Glu31Lys) <em>LDLR</em> variant showed fully functional low-density lipoprotein binding and uptake activities. These results suggested that c.91G &gt; A p. (Glu31Lys) is unlikely to be a disease-causing variant.</div></div><div><h3>Conclusions</h3><div>The results provide functional evidence for the activity of selected <em>LDLR</em> variants in a cellular model based on confocal techniques that meets the ACMG/AMP variant classification criteria. These findings highlight the importance of <em>in vitro</em> assays in evaluating the functional impact of <em>LDLR</em> variants and contribute valuable insights for clinical interpretation and genetic counseling.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 30-37"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone Undecanoate Significantly Reduces LDL-Cholesterol and Triglycerides in Men with Adult-Onset Testosterone Deficiency","authors":"Anirudh Bhat ,&nbsp;Arjun Ajith Kumar ,&nbsp;Farid Saad ,&nbsp;Karim Sultan Haider ,&nbsp;Ahmad Haider ,&nbsp;Sudarshan Ramachandran","doi":"10.1016/j.athplu.2025.10.008","DOIUrl":"10.1016/j.athplu.2025.10.008","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 5"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a diagnostic score to identify children with Familial Hypercholesterolaemia – The Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS)","authors":"J. Kafol ,&nbsp;B. Miranda ,&nbsp;R. Sikonja ,&nbsp;J. Sikonja ,&nbsp;A. Wiegman ,&nbsp;FH-PeDS Collaborators,&nbsp;S.E. Humphries ,&nbsp;M. Bourbon ,&nbsp;U. Groselj","doi":"10.1016/j.athplu.2025.10.005","DOIUrl":"10.1016/j.athplu.2025.10.005","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 3"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world safety and effectiveness of lomitapide in homozygous familial hypercholesterolaemia over ten years: Data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","authors":"Jaimini Cegla ,&nbsp;Dirk Blom ,&nbsp;James Underberg ,&nbsp;Christopher P. Cannon ,&nbsp;Dominique Larrey ,&nbsp;Lukas Makris ,&nbsp;Inbar Aviezer ,&nbsp;Ruth Louzado ,&nbsp;Sandra Löwe ,&nbsp;Sallyann O’Brien","doi":"10.1016/j.athplu.2025.10.014","DOIUrl":"10.1016/j.athplu.2025.10.014","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 8"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chylomicronaemia secondary to GPIHBP1 autoantibodies giving rise to functional LPL deficiency: is this an under-recognised rare explanation for those with an otherwise unexplained secondary hypertriglyceridaemia?","authors":"N.W.P. Cantley ,&nbsp;S. Tapley ,&nbsp;M. Murakami ,&nbsp;K. Nakajima ,&nbsp;P. Downie","doi":"10.1016/j.athplu.2025.10.011","DOIUrl":"10.1016/j.athplu.2025.10.011","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 6"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic and regional trends of mortality in patients with cardiovascular disease and liver cirrhosis in the United States between 1999 and 2019","authors":"Farah Yasmin ,&nbsp;Abdul Moeed ,&nbsp;Muhammad Ahmed Ali Fahim ,&nbsp;Gaurav Kumar ,&nbsp;Maryam Shaharyar ,&nbsp;Muhammad Sohaib Asghar","doi":"10.1016/j.athplu.2025.09.004","DOIUrl":"10.1016/j.athplu.2025.09.004","url":null,"abstract":"<div><h3>Objectives</h3><div>National estimates of deaths related to cardiovascular disease (CVD) and liver cirrhosis remain ambiguous. The purpose of this study was to observe the contemporary trends in CVD and liver cirrhosis-related mortality in the United States.</div></div><div><h3>Methods</h3><div>We evaluated the trends using the CDC WONDER database to identify adults with CVD and liver cirrhosis associated death between 1999 and 2019. Age-adjusted mortality rates (AAMRs) per 100,000 population and associated average annual percent changes (AAPCs) with 95 % confidence intervals (CIs) were assessed using Joinpoint regression.</div></div><div><h3>Results</h3><div>Between 1999 and 2019, a total of 374,090 deaths occurred due to CVD and liver cirrhosis. In the overall population, the AAMR increased from 7.54 (95 % CI 7.41–7.67) in 1999 to 10.55 (95 % CI 10.43–10.68) with an AAPC of 1.68 (95 % CI 1.59–1.77). The highest AAMRs were seen in males, Native Americans, and those living in West. A substantial increase in AAMRs was observed in all age groups with the highest seen in 70–84 year group. Moreover, non-metropolitan cities had a much higher increase in AAMRs compared to large metropolitan cities. The highest AAMRs were observed in California whereas the lowest in Utah.</div></div><div><h3>Conclusion</h3><div>There is a rising trend of CVD and liver cirrhosis-associated mortality in all groups. However, disparities continue to exist in association with gender, race, age, and geographical region. Future trials should address alleviating CVD and liver cirrhosis-related deaths in all population groups equitably.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}